Intuitive Surgical ($ISRG) Set to Release its Financial Results
This week, Intuitive Surgical (NASDAQ: 
ISRG) is set to release its financial results, and its stock price is expected to be in the spotlight. The robotics industry giant's product, da Vinci, is utilized by numerous doctors for performing minimally invasive surgeries. Intuitive Surgical's performance has been noteworthy in recent years, with a surge in demand for its product. Consequently, its total revenue increased from $4.47 billion in 2019 to over $7.1 billion in 2023.
In the fourth quarter of the previous year, the company reported a 17% increase in revenue to $1.66 billion, with a 22% rise in its instruments and accessories business generating $1.14 billion in revenue. Additionally, the company's revenue from its systems rose to $480 million, with 415 da Vinci surgical systems sold in comparison to 369 in the same period in 2023.
This week's earnings report is expected to have a significant impact on the ISRG stock price. Analysts predict that the company's revenue for Q1 will improve from $1.65 billion last year to $1.81 billion. The company's growth is expected to continue, with investors anticipating revenue of $1.98 billion in Q2. The average estimate for the year is that its revenue will reach $8 billion, followed by $9.24 billion in 2026.
Intuitive Surgical's (ISRG) strong device sales and recurring revenue, combined with its robust balance sheet, have led analysts to be bullish on the company's prospects. The company has a cash and equivalents balance of more than $7.34 billion and minimal debt. In the last quarter, it generated over $92.6 million in interest income.
Recently, Stifel, Citigroup, Mizuho, and Barclays have upgraded the stock, with an average target of $414.80, higher than the current $378.55. TheISRG shares peaked at $403.97 in March, a 123% increase from its lowest point in 2022. However, the stock has pulled back as some investors took profits while awaiting the financial results.
Intuitive Surgical's stock has retested the crucial support level at $370, which was its highest swing in December last year. Typically, a break and retest pattern is a bullish sign in the market. The only potential risk is that it has formed a double-top pattern near $403. The key support and resistance levels to watch are $360 (July 23rd high) and $403, respectively.
In conclusion, Intuitive Surgical's financial results this week are anticipated to be a significant factor in determining the company's future stock performance. The company's strong balance sheet, recurring revenue, and robust device sales are among the factors that have led industry analysts to be optimistic about the company's prospects.
ISRG) is set to release its financial results, and its stock price is expected to be in the spotlight. The robotics industry giant's product, da Vinci, is utilized by numerous doctors for performing minimally invasive surgeries. Intuitive Surgical's performance has been noteworthy in recent years, with a surge in demand for its product. Consequently, its total revenue increased from $4.47 billion in 2019 to over $7.1 billion in 2023.In the fourth quarter of the previous year, the company reported a 17% increase in revenue to $1.66 billion, with a 22% rise in its instruments and accessories business generating $1.14 billion in revenue. Additionally, the company's revenue from its systems rose to $480 million, with 415 da Vinci surgical systems sold in comparison to 369 in the same period in 2023.
This week's earnings report is expected to have a significant impact on the ISRG stock price. Analysts predict that the company's revenue for Q1 will improve from $1.65 billion last year to $1.81 billion. The company's growth is expected to continue, with investors anticipating revenue of $1.98 billion in Q2. The average estimate for the year is that its revenue will reach $8 billion, followed by $9.24 billion in 2026.
Intuitive Surgical's (
ISRG) strong device sales and recurring revenue, combined with its robust balance sheet, have led analysts to be bullish on the company's prospects. The company has a cash and equivalents balance of more than $7.34 billion and minimal debt. In the last quarter, it generated over $92.6 million in interest income.Recently, Stifel, Citigroup, Mizuho, and Barclays have upgraded the stock, with an average target of $414.80, higher than the current $378.55. The
ISRG shares peaked at $403.97 in March, a 123% increase from its lowest point in 2022. However, the stock has pulled back as some investors took profits while awaiting the financial results.Intuitive Surgical's stock has retested the crucial support level at $370, which was its highest swing in December last year. Typically, a break and retest pattern is a bullish sign in the market. The only potential risk is that it has formed a double-top pattern near $403. The key support and resistance levels to watch are $360 (July 23rd high) and $403, respectively.
In conclusion, Intuitive Surgical's financial results this week are anticipated to be a significant factor in determining the company's future stock performance. The company's strong balance sheet, recurring revenue, and robust device sales are among the factors that have led industry analysts to be optimistic about the company's prospects.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.